179 related articles for article (PubMed ID: 33903614)
1. SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer.
Zhao W; Sun L; Li X; Wang J; Zhu Y; Jia Y; Tong Z
Sci Rep; 2021 Apr; 11(1):8976. PubMed ID: 33903614
[TBL] [Abstract][Full Text] [Related]
2. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
3. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Cerbelli B; Pernazza A; Botticelli A; Fortunato L; Monti M; Sciattella P; Campagna D; Mazzuca F; Mauri M; Naso G; Marchetti P; d'Amati G; Costarelli L
Biomed Res Int; 2017; 2017():1750925. PubMed ID: 29387716
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker.
Singh A; Bandyopadhyay A; Mukherjee N; Basu A
Genet Test Mol Biomarkers; 2021 Jan; 25(1):12-19. PubMed ID: 33372855
[No Abstract] [Full Text] [Related]
9. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Babyshkina N; Zavyalova M; Tarabanovskaya N; Dronova T; Krakhmal N; Slonimskaya E; Kzhyshkowska J; Choynzonov E; Cherdyntseva N
Mol Cell Biochem; 2018 Jul; 444(1-2):197-206. PubMed ID: 29230610
[TBL] [Abstract][Full Text] [Related]
11. Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Ritter A; Hirschfeld M; Berner K; Rücker G; Jäger M; Weiss D; Medl M; Nöthling C; Gassner S; Asberger J; Erbes T
Int J Oncol; 2020 Jan; 56(1):47-68. PubMed ID: 31789396
[TBL] [Abstract][Full Text] [Related]
12. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
[TBL] [Abstract][Full Text] [Related]
13. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
14. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
15. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
16. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
17. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
18. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
20. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
